期刊文献+

晚期糖基化终产物诱导人近端肾小管上皮细胞纤溶酶原激活物抑制剂-1表达上调并活化NADPH氧化酶 被引量:3

Advanced glycation end products induce expression of PAI-1 in cultured human proximal tubular epithelial cells through NADPH oxidase dependent pathway
下载PDF
导出
摘要 目的:研究晚期糖基化终产物(AGES)修饰蛋白诱导人近端肾小管上皮HK-2细胞分泌纤溶酶原激活物抑制剂-1(PAI-1)的影响及其相关的氧化应激传导途径。方法:采用不同浓度AGES修饰的人血清白蛋白(AGES-HSA)与肾小管上皮HK-2细胞共培养。用光泽精化学发光法检测细胞匀浆中NADPH氧化酶活性,ELISA检测细胞上清液中PAI-1蛋白分泌,RT-PCR法检测PAI-1mRNA表达。结果:AGES-HSA诱导HK-2细胞NADPH氧化酶活化,并以时间、剂量依赖方式上调PAI-1蛋白和mRNA的表达。运用NADPH氧化酶抑制剂DPI、apocynin、氧自由基清除剂SOD可以明显阻断AG-ES-HSA诱导的PAI-1表达。结论:AGES-HSA可通过NADPH氧化酶依赖的氧化应激途径上调肾小管上皮细胞PAI-1表达。 AIM: To investigate the effects of advanced glycation end products (AGES) on secretion of plasmino- gen activator inhibitor-1 ( PAI-1 ) by human proximal tubular epithelial cells and its NADPH oxidase dependent pathway. METHODS: Human proximal tubular epithelial cells were cultured in vitro with indicated concentration of AGES modi- fied human serum albumin (AGES-HSA). NADPH oxidase activity were detected by lucigenin-enhanced chemiluminescence. The production of PAI-1 was evaluated by enzymelinked immunoadsorbent assay (ELISA). The PAI-1 mRNA expression was assayed by reverse transcription polymerase chain reaction (RT-PCR), RESULTS: AGES-HSA were associated with enhanced oxidative stress and NADPH oxidase activity. AGES-HSA upregulated the expression of PAI-1 mRNA and protein with dose and time dependent fashion. AGES-HSA-induced PAI-1 expression were significantly suppressed by the NAD(P) H oxidase inhibitors DPI, apocynin or O2- scavenger SOD. CONCLUSION: AGESHSA stimulate tubular epithelial cells to produce PAI-1 through activation of NADPH oxidase.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2009年第8期674-677,共4页 Chinese Journal of Cellular and Molecular Immunology
关键词 晚期糖基化终产物 肾小管上皮细胞 纤溶酶原激活物抑制剂-1 活性氧 NADPH氧化酶 glycosylation end products tubular epithelial cells PAI-1 reactive oxygen species NAD- PH oxidase
  • 相关文献

参考文献1

二级参考文献25

  • 1Nakamura S,Nakamura I,Ma L,et al. Plasminogen activator inhibitor- 1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int,2000,58:251 - 259.
  • 2Jiang Z, Seo JY, Ha H, et al. Reactive oxygen species mediate TGF- beta1 - induced plasminogen activator inhibitor - 1 upregulation in mesangial cells. Biochem Biophys Res Commun,2003,309(4) :961 - 6.
  • 3McMahon GA,Petitclerc E,Stefansson S,et al. Plasminogen activator inhibitor- 1 regulates tumor growth and angiogenesis. J Biol Chem, 2001,276(36) :33964 - 8.
  • 4Devy L, Blacher S, Grignet- Debrus C, et al. The proor antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J,2002,16(2): 147 - 54.
  • 5Degryse B,Sier CF, Resnati M,et al. PAI- 1 inhibits urokinase- induced chemotaxis by internalizing the urokinase receptor. FEBS Lett, 2001,505(2) :249 - 54.
  • 6Oda T, Jung YO, Kim H, et al. PAI- 1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int,2001,60(2) :587 - 96.
  • 7Sitrin RG,PanPM,BlackwoodRA,etal. Cutting edge : evidence for a signaling partnership between urokinase receptors(CD87) and L- se1ectin (CD62L) in human polymorphonuclear neutrophils. J Immunol,2001,166(8) :4822 - 25.
  • 8Gyetko MR, Sud S, Sonstein J, et al. Cutting edge: antigen - driven lymphocyte recruitment to the lung is diminished in the absence of urokinase - type plasminogen activator(uPA) receptor, but is independent of uPA. J Immunol,2001,167(10) :5539 - 42.
  • 9Zhang G, Kim H, Cai X, et al. Urokinase receptor deficiency modulates cellular and angiogenic responses in obstructive uropathy. J Am Soc Nephrol,2001,12:723.
  • 10Martin AA, Woolven BL, Harris SJ, et al. Plasminogen activator inhibitor type- 1 and interleukin- 6 in haemolytic uraemic syndrome. J Paediatr Child Health,2000,36:327 - 31.

共引文献2

同被引文献21

  • 1Tucker PS, Dalbo VJ, Han T, et al. Clinical and research markers ofoxidative stress in chronic kidney disease[J]. Biomarkers, 2013, 18(2): 103-15.
  • 2Selmeci L. Advanced oxidation protein products (AOPP): noveluremic toxins, or components of the non-enzymatic antioxidantsystem of the plasma proteome[J]. Free Radic Res, 2011, 45(10):1115-23.
  • 3iu SX, Hou FF, Guo ZJ, et al. Advanced oxidation protein productsaccelerate atherosclerosis through promoting oxidative stress andinflammation[J]. Arterioscler Thromb Vasc Biol, 2006, 26(5):1156-62.
  • 4Demirci S, Sekero?lu MR, Noyan T, et al. The importance ofoxidative stress in patients with chronic renal failure whosehypertension is treated with peritoneal dialysis[J]. Cell BiochemFunct, 2011, 29(3): 249-54.
  • 5Coppo R, Camilla R, Amore A, et al. Oxidative stress in IgAnephropathy [J]. Nephron Clin Pract, 2010, 116(3): c196-8,discussion c199.
  • 6Gradinaru D, Borsa C, Ionescu C, et al. Advanced oxidative andglycoxidative protein damage markers in the elderly with type 2diabetes[J]. J Proteomics, 2013, 92: 313-22.
  • 7Sedeek M, Nasrallah R, Touyz RM, et al. NADPH oxidases,reactive Oxygen species, and the kidney: friend and foe[J]. J AmSoc Nephrol, 2013, 24(10): 1512-8.
  • 8Small DM, Coombes JS, Bennett N, et al. Oxidative stress, antioxidanttherapies and chronic kidney disease[J]. Nephrology(Carlton), 2012, 17(4): 311-21.
  • 9Qi W, Niu J, Qin Q, et al. Astragaloside IV attenuates glycatedalbumin-induced epithelial-to-mesenchymal transition by inhibitingoxidative stress in renal proximal tubular cells[J]. Cell StressChaperones, 2014, 19(1): 105-14.
  • 10Watanabe H, Miyamoto Y, Honda D, et al. p-Cresyl sulfate causesrenal tubular cell damage by inducing oxidative stress by activationof NADPH oxidase[J]. Kidney Int, 2013, 83(4): 582-92.

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部